Milestone Asset Management LLC Buys 7,513 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Milestone Asset Management LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 50.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,277 shares of the biopharmaceutical company's stock after purchasing an additional 7,513 shares during the quarter. Milestone Asset Management LLC's holdings in Gilead Sciences were worth $2,058,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Baader Bank Aktiengesellschaft grew its position in shares of Gilead Sciences by 208.4% in the 4th quarter. Baader Bank Aktiengesellschaft now owns 10,844 shares of the biopharmaceutical company's stock worth $1,002,000 after buying an additional 7,328 shares during the period. Foster & Motley Inc. grew its position in shares of Gilead Sciences by 80.4% in the 4th quarter. Foster & Motley Inc. now owns 10,587 shares of the biopharmaceutical company's stock worth $978,000 after buying an additional 4,718 shares during the period. Swedbank AB grew its position in shares of Gilead Sciences by 2.7% in the 4th quarter. Swedbank AB now owns 2,101,969 shares of the biopharmaceutical company's stock worth $194,159,000 after buying an additional 54,360 shares during the period. Strategic Blueprint LLC grew its position in shares of Gilead Sciences by 7.5% in the 4th quarter. Strategic Blueprint LLC now owns 2,750 shares of the biopharmaceutical company's stock worth $254,000 after buying an additional 192 shares during the period. Finally, Asset Dedication LLC grew its position in shares of Gilead Sciences by 43.3% in the 4th quarter. Asset Dedication LLC now owns 6,421 shares of the biopharmaceutical company's stock worth $593,000 after buying an additional 1,940 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $1.23 during trading on Thursday, hitting $96.82. The company's stock had a trading volume of 2,094,775 shares, compared to its average volume of 6,542,193. The company has a 50-day moving average of $92.14 and a 200-day moving average of $85.51. The firm has a market cap of $120.66 billion, a price-to-earnings ratio of 1,074.60, a P/E/G ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.29 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Robert W. Baird upped their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a research note on Thursday, November 7th. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price target on the stock. Maxim Group cut shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $84.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $98.39.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock valued at $42,130,461 in the last three months. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.